¼¼°èÀÇ Pharma 4.0 ½ÃÀå º¸°í¼­(2025³â)
Pharma 4.0 Global Market Report 2025
»óǰÄÚµå : 1694758
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,339,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,163,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,987,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Pharma 4.0 ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ºñ¾àÀûÀÎ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö ¿¬Æò±Õ 20.8%ÀÇ ¼ºÀå·ü·Î 464¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº °¡Ä¡ ±â¹Ý ÀÇ·á ¸ðµ¨·ÎÀÇ Àüȯ, °í·ÉÈ­ ¹× ÀÇ·á ¼ö¿ä Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹× Á¤¹Ð Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä, ±ÔÁ¦ °³Çõ ¹× ÀÇ·á Á¤Ã¥ÀÇ º¯È­, ȯÀÚ Áß½É Ä¡·á ¹× °á°ú¿¡ ´ëÇÑ Á߿伺 Áõ°¡¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹× Á¤¹Ð Ä¡·á, µðÁöÅÐ ÇコÄÉ¾î ±â¼ú, °¡Ä¡ ±â¹Ý ÇコÄÉ¾î ¸ðµ¨, ±ÔÁ¦ Á¶È­ ¹× ½ÂÀÎ ÇÁ·Î¼¼½º °¡¼ÓÈ­, °ø±Þ¸Á µðÁöÅÐÈ­ ¹× Åõ¸í¼º µîÀÌ ÀÖ½À´Ï´Ù.

¿ø°ÝÀÇ·á¿Í ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ È®´ë°¡ ÇâÈÄ Pharma 4.0 ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ø°Ý ÀÇ·á´Â Åë½Å ±â¼úÀ» ÅëÇØ ¿ø°ÝÁö¿¡¼­ ÀÇ·á ¹× Áø·á¸¦ Á¦°øÇÏ´Â °ÍÀ̸ç, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀº ±â¼ú Áö¿ø ÀåÄ¡ ¹× Ç÷§ÆûÀ» »ç¿ëÇÏ¿© ¿ø°ÝÁö¿¡¼­ ȯÀÚÀÇ °Ç°­ µ¥ÀÌÅ͸¦ ¼öÁý, Àü¼Û, ºÐ¼®ÇÏ´Â °ÍÀÔ´Ï´Ù. ¿ø°Ý ÀÇ·á¿Í ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀº ¸ðµÎ ±â¼úÀÇ ¹ßÀü, Æí¸®ÇÑ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, È¿À²ÀûÀÎ ¸¸¼º Áúȯ °ü¸®ÀÇ Çʿ伺¿¡ µû¶ó ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ȯÀÚ Áß½É Ä¡·á, °³ÀÎ ¸ÂÃãÇü ÀǷḦ À§ÇÑ ½Ç½Ã°£ µ¥ÀÌÅÍ ¼öÁý, ÀǾàǰ °³¹ßÀ» À§ÇÑ Á¦¾à»çÀÇ ÅëÂû·Â °­È­ µîÀ» °¡´ÉÇÏ°Ô Çϸç, Pharma 4.0¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù Australian Digital Health Agency¿¡ µû¸£¸é 2020³â 3¿ù 13ÀϺÎÅÍ 2022³â 7¿ù 31ÀϱîÁö 1¾ï 1,820¸¸ °ÇÀÇ ¿ø°ÝÀÇ·á ¼­ºñ½º°¡ 1,800¸¸ ¸íÀÇ È¯ÀÚ¿¡°Ô Á¦°øµÇ¾ú°í, 2022³â¿¡´Â 95,000¸í ÀÌ»óÀÇ °³¾÷Àǰ¡ ¿ø°ÝÀÇ·á ¼­ºñ½º¸¦ ÀÌ¿ëÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á ¼­ºñ½º¸¦ ÀÌ¿ëÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ¿ø°ÝÀÇ·á¿Í ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ È®´ë°¡ Pharma 4.0 ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Pharma 4.0 ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº Ŭ¶ó¿ìµå ±â¹Ý ½Å¾à°³¹ß Ç÷§Æû°ú °°Àº Çõ½ÅÀûÀÎ ±â¼úÀ» Ȱ¿ëÇÏ¿© °æÀï·ÂÀ» È®º¸Çϰí ÀÖÀ¸¸ç, StarDrop°ú °°Àº Ç÷§ÆûÀº ÀÎÅͳÝÀ» ÅëÇØ Á¢±Ù °¡´ÉÇÑ Å¬¶ó¿ìµå È£½ºÆÃ ȯ°æÀ» ¿¬±¸ÀÚ ¹× Á¦¾àȸ»ç¿¡ Á¦°øÇÏ¿© È­ÇÕ¹° ½ºÅ©¸®´×, ºÐÀÚ ¸ðµ¨¸µ, µ¥ÀÌÅÍ ºÐ¼® µî ´Ù¾çÇÑ ½Å¾à°³¹ß Ȱµ¿À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. È­ÇÕ¹° ½ºÅ©¸®´×, ºÐÀÚ ¸ðµ¨¸µ, µ¥ÀÌÅÍ ºÐ¼® µî ´Ù¾çÇÑ ½Å¾à°³¹ß Ȱµ¿À» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Optibrium Ltd.´Â 2023³â 10¿ù À¯¸í ½Å¾à°³¹ß Ç÷§ÆûÀÎ StarDropÀÇ Å¬¶ó¿ìµå ±â¹Ý ¹öÀüÀ» Á¦°øÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ÀÌ Å¬¶ó¿ìµå ±â¹Ý ¹èÆ÷´Â µ¥½ºÅ©Åé ¿ëµµÀÇ ¸ðµç ±â´ÉÀ» À¯ÁöÇϸ鼭 Á¢±Ù¼ºÀ» °­È­Çϰí ÃѼÒÀ¯ºñ¿ëÀ» ³·Ã߸ç, Amazon Web Services(AWS)¿¡¼­ È£½ºÆÃµÇ°í OptibriumÀÇ ISO 27001 ÀÎÁõ Á¤º¸ º¸¾È ½Ã½ºÅÛÀ» ÅëÇØ Áö¿øµË´Ï´Ù. ½Ã½ºÅÛ¿¡¼­ Áö¿øÇÏ´Â ÀÌ Ç÷§ÆûÀº ¾ÈÀüÇÑ µ¥ÀÌÅÍ Àü¼ÛÀ» À§ÇÑ ¾Ïȣȭ ¹× ¹æÈ­º® º¸È£¸¦ Æ÷ÇÔÇÑ ³ôÀº ¼öÁØÀÇ µ¥ÀÌÅÍ º¸¾ÈÀ» º¸ÀåÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Pharma 4.0, also termed Pharmaceutical 4.0, signifies the integration of advanced digital technologies within the pharmaceutical sector, akin to the broader concept of Industry 4.0. It represents a transformative approach to pharmaceutical manufacturing and healthcare delivery, aimed at addressing challenges such as rising costs, regulatory compliance, drug shortages, and the demand for personalized treatments. Moreover, it aims to unlock new avenues for innovation while enhancing patient care.

The primary components of Pharma 4.0 include hardware, software, and services. Hardware refers to the physical components of computer systems or electronic devices, encompassing elements such as processors, memory, storage, and peripherals. Various cutting-edge technologies, including cloud computing, artificial intelligence (AI), big data analytics, and the Internet of Things (IoT), are leveraged across numerous applications within the pharmaceutical sector, ranging from drug discovery and development to clinical trials and manufacturing processes. Pharma 4.0 solutions find application across a diverse range of end-users, primarily including pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and contract manufacturing organizations (CMOs).

The pharma 4.0 market research report is one of a series of new reports from The Business Research Company that provides pharma 4.0 market statistics, including pharma 4.0 industry global market size, regional shares, competitors with a pharma 4.0 market share, detailed pharma 4.0 market segments, market trends and opportunities, and any further data you may need to thrive in the pharma 4.0 industry. This pharma 4.0 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharma 4.0 market size has grown exponentially in recent years. It will grow from $17.99 billion in 2024 to $21.77 billion in 2025 at a compound annual growth rate (CAGR) of 21.0%. The growth in the historic period can be attributed to regulatory compliance and quality assurance, drug patent expirations and generic competition, increasing healthcare expenditure, demand for personalized medicine and biologics, globalization of pharmaceutical markets.

The pharma 4.0 market size is expected to see exponential growth in the next few years. It will grow to $46.41 billion in 2029 at a compound annual growth rate (CAGR) of 20.8%. The growth in the forecast period can be attributed to shift towards value-based healthcare models, aging population and increased healthcare needs, demand for personalized medicine and precision therapeutics, regulatory reforms and changes in healthcare policies, growing emphasis on patient-centric care and outcomes. Major trends in the forecast period include personalized medicine and precision therapeutics, digital health technologies, value-based healthcare models, regulatory harmonization and accelerated approval processes, supply chain digitization and transparency.

The expansion of telemedicine and remote patient monitoring is expected to drive the growth of the Pharma 4.0 market moving forward. Telemedicine involves providing medical care and consultations remotely through telecommunications technology, while remote patient monitoring collects, transmits, and analyzes patient health data from a distance using technology-enabled devices and platforms. Both telemedicine and remote patient monitoring are growing due to technological advancements, increasing demand for convenient healthcare access, and the need for efficient chronic disease management. These technologies play vital roles in Pharma 4.0 by enabling patient-centered care, real-time data collection for personalized medicine, and enhancing pharmaceutical companies' ability to gather insights for drug development. For example, according to the Australian Digital Health Agency in August 2022, from 13 March 2020 to 31 July 2022, 118.2 million telehealth services were delivered to 18 million patients, with over 95,000 practitioners using telehealth services in 2022. Therefore, the expansion of telemedicine and remote patient monitoring is contributing to the growth of the Pharma 4.0 market.

Key players in the pharma 4.0 market are leveraging innovative technologies such as cloud-based drug discovery platforms to gain a competitive edge. Platforms such as StarDrop offer researchers and pharmaceutical companies cloud-hosted environments accessible via the Internet, enabling various drug discovery activities such as compound screening, molecular modeling, and data analysis. For example, Optibrium Ltd. launched a cloud-based version of its renowned drug discovery platform, StarDrop, in October 2023. This cloud-based deployment enhances accessibility and reduces total ownership costs while retaining all functionalities of the desktop application. Hosted on Amazon Web Services (AWS) and supported by Optibrium's ISO 27001-accredited information security system, the platform ensures advanced data security, including encryption for secure data transfer and protection behind a firewall.

In June 2022, ProductLife Group bolstered its presence in the pharma 4.0 market through the acquisition of Pharma IT ApS. This strategic move aims to enhance ProductLife Group's market position, particularly in Northern Europe, and expand its service offerings in life sciences digitalization. Pharma IT ApS, a Denmark-based consulting company specializing in life sciences, brings valuable expertise in consulting services for the medical device, biotech, and pharmaceutical industries, strengthening ProductLife Group's capabilities in catering to the evolving needs of the pharma 4.0 landscape.

Major companies operating in the pharma 4.0 market are Alphabet Inc., Microsoft Corporation, Pfizer Inc., Johnson & Johnson, Amazon Web Services Inc., Roche Holding AG, International Business Machines Corporation, Merck & Co. Inc., Cisco Systems Inc., Bristol Myers Squibb Company, Oracle Corporation, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Honeywell International Inc., Fujitsu Limited, ABB Ltd., Siemens Healthineers, GE Healthcare, Lotte Corporation, SAS Institute Inc., Optum Inc., POLARISqb, Syntekabio, Optibrium

North America was the largest region in the pharma 4.0 market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the pharma 4.0 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pharma 4.0 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharma 4.0 market consists of revenues earned by entities by providing services such as remote patient monitoring, virtual consultations, digital therapeutics, and medication adherence programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The Pharma 4.0 market also includes sales of digital twin platforms, smart manufacturing systems, patient engagement tools, and monitoring tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharma 4.0 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharma 4.0 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pharma 4.0 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharma 4.0 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pharma 4.0 Market Characteristics

3. Pharma 4.0 Market Trends And Strategies

4. Pharma 4.0 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Pharma 4.0 Growth Analysis And Strategic Analysis Framework

6. Pharma 4.0 Market Segmentation

7. Pharma 4.0 Market Regional And Country Analysis

8. Asia-Pacific Pharma 4.0 Market

9. China Pharma 4.0 Market

10. India Pharma 4.0 Market

11. Japan Pharma 4.0 Market

12. Australia Pharma 4.0 Market

13. Indonesia Pharma 4.0 Market

14. South Korea Pharma 4.0 Market

15. Western Europe Pharma 4.0 Market

16. UK Pharma 4.0 Market

17. Germany Pharma 4.0 Market

18. France Pharma 4.0 Market

19. Italy Pharma 4.0 Market

20. Spain Pharma 4.0 Market

21. Eastern Europe Pharma 4.0 Market

22. Russia Pharma 4.0 Market

23. North America Pharma 4.0 Market

24. USA Pharma 4.0 Market

25. Canada Pharma 4.0 Market

26. South America Pharma 4.0 Market

27. Brazil Pharma 4.0 Market

28. Middle East Pharma 4.0 Market

29. Africa Pharma 4.0 Market

30. Pharma 4.0 Market Competitive Landscape And Company Profiles

31. Pharma 4.0 Market Other Major And Innovative Companies

32. Global Pharma 4.0 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharma 4.0 Market

34. Recent Developments In The Pharma 4.0 Market

35. Pharma 4.0 Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â